Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2015 May 1;33(13):1460-6.
doi: 10.1200/JCO.2014.55.9898. Epub 2015 Mar 23.

Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study

Devansu Tewari  1 , James J Java  1 , Ritu Salani  1 , Deborah K Armstrong  1 , Maurie Markman  1 , Thomas Herzog  1 , Bradley J Monk  1 , John K Chan  2
Affiliations
Comparative Study

Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study

Devansu Tewari et al. J Clin Oncol. .

Erratum in

  • ERRATUM.
    [No authors listed] [No authors listed] J Clin Oncol. 2015 Nov 1;33(31):3678. doi: 10.1200/JCO.2015.64.1083. J Clin Oncol. 2015. PMID: 26515827 Free PMC article. No abstract available.

Abstract

Purpose: To determine long-term survival and associated prognostic factors after intraperitoneal (IP) chemotherapy in patients with advanced ovarian cancer.

Patients and methods: Data from Gynecologic Oncology Group protocols 114 and 172 were retrospectively analyzed. Cox proportional hazards regression models were used for statistical analyses.

Results: In 876 patients, median follow-up was 10.7 years. Median survival with IP therapy was 61.8 months (95% CI, 55.5 to 69.5), compared with 51.4 months (95% CI, 46.0 to 58.2) for intravenous therapy. IP therapy was associated with a 23% decreased risk of death (adjusted hazard ratio [AHR], 0.77; 95% CI, 0.65 to 0.90; P = .002). IP therapy improved survival of those with gross residual (≤ 1 cm) disease (AHR, 0.75; 95% CI, 0.62 to 0.92; P = .006). Risk of death decreased by 12% for each cycle of IP chemotherapy completed (AHR, 0.88; 95% CI, 0.83 to 0.94; P < .001). Factors associated with poorer survival included: clear/mucinous versus serous histology (AHR, 2.79; 95% CI, 1.83 to 4.24; P < .001), gross residual versus no visible disease (AHR, 1.89; 95% CI, 1.48 to 2.43; P < .001), and fewer versus more cycles of IP chemotherapy (AHR, 0.88; 95% CI, 0.83 to 0.94; P < .001). Younger patients were more likely to complete the IP regimen, with a 5% decrease in probability of completion with each year of age (odds ratio, 0.95; 95% CI, 0.93 to 0.96; P < .001).

Conclusion: The advantage of IP over intravenous chemotherapy extends beyond 10 years. IP therapy enhanced survival of those with gross residual disease. Survival improved with increasing number of IP cycles.

PubMed Disclaimer

Conflict of interest statement

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Figures

Fig 1.
Fig 1.
CONSORT diagram. GOG, Gynecologic Oncology Group; IP, intraperitoneal; IV, intravenous.
Fig 2.
Fig 2.
Long-term overall survival of patients treated with intravenous (IV) versus intraperitoneal (IP) chemotherapy (P = .04).
Fig 3.
Fig 3.
Long-term overall survival of patients treated with intravenous (IV) versus intraperitoneal (IP) chemotherapy based on extent of residual disease (DS; P < .001). NOTE. Gross residual defined as ≤ 1 cm; micro residual defined as no visible disease.
Fig 4.
Fig 4.
Long-term overall survival based on number of cycles of intraperitoneal (IP) therapy (P = .03). Analysis restricted to patients in Gynecologic Oncology Group (GOG) -0172 who completed all six cycles of chemotherapy (both IP and intravenous [IV] arms).
Fig A1.
Fig A1.
Long-term overall survival after intravenous (IV) versus intraperitoneal (IP) therapy based on Gynecologic Oncology Group (GOG) protocols 0114 and 0172.
See this image and copyright information in PMC

Comment in

References

    1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30. - PubMed
    1. American Cancer Society. Cancer facts and figures 2012. http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/docume....
    1. Chan JK, Cheung MK, Husain A, et al. Patterns and progress in ovarian cancer over 14 years. Obstet Gynecol. 2006;108:521–528. - PubMed
    1. Lopez JA, Krikorian JG, Reich SD, et al. Clinical pharmacology of intraperitoneal cisplatin. Gynecol Oncol. 1985;20:1–9. - PubMed
    1. Pretorius RG, Hacker NF, Berek JS, et al. Pharmacokinetics of IP cisplatin in refractory ovarian carcinoma. Cancer Treat Rep. 1983;67:1085–1092. - PubMed

Publication types

MeSH terms